• Je něco špatně v tomto záznamu ?

Substituted dienes prepared from betulinic acid - Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters

J. Pokorný, D. Olejníková, I. Frydrych, B. Lišková, S. Gurská, S. Benická, J. Šarek, J. Kotulová, M. Hajdúch, P. Džubák, M. Urban

. 2021 ; 224 (-) : 113706. [pub] 20210715

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011928

A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011928
003      
CZ-PrNML
005      
20220506125855.0
007      
ta
008      
220425s2021 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2021.113706 $2 doi
035    __
$a (PubMed)34311159
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Pokorný, Jan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. Listopadu 1192/12, 771 46, Olomouc, Czech Republic
245    10
$a Substituted dienes prepared from betulinic acid - Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters / $c J. Pokorný, D. Olejníková, I. Frydrych, B. Lišková, S. Gurská, S. Benická, J. Šarek, J. Kotulová, M. Hajdúch, P. Džubák, M. Urban
520    9_
$a A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.
650    _2
$a alkadieny $x chemická syntéza $x chemie $x farmakologie $7 D000466
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a kultivované buňky $7 D002478
650    _2
$a psi $7 D004285
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a pentacyklické triterpeny $x chemie $x farmakologie $7 D053978
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Olejníková, Denisa $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. Listopadu 1192/12, 771 46, Olomouc, Czech Republic
700    1_
$a Frydrych, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Lišková, Barbora $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Benická, Sandra $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. Listopadu 1192/12, 771 46, Olomouc, Czech Republic
700    1_
$a Šarek, Jan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. Listopadu 1192/12, 771 46, Olomouc, Czech Republic
700    1_
$a Kotulová, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic
700    1_
$a Urban, Milan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, 779 00, Olomouc, Czech Republic. Electronic address: milan.urban@upol.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 224, č. - (2021), s. 113706
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34311159 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125847 $b ABA008
999    __
$a ok $b bmc $g 1789500 $s 1163129
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 224 $c - $d 113706 $e 20210715 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...